A Multicenter, Randomized, Double-blind, Active-controlled Parallel-group Phase ii Clinical Study to Compare the Efficacy and Safety of SHR4640 Tablets Combined With Febuxostat Tablets at 40 mg/Day Versus Febuxostat Tablets With Dose Escalation in Treatment of Primary Gout and Hyperuricemia Subjects With Inadequate Control on 40 mg/Day Febuxostat
Latest Information Update: 10 Feb 2026
At a glance
- Drugs Febuxostat (Primary) ; Ruzinurad (Primary)
- Indications Gout; Hyperuricaemia
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 05 Feb 2026 Planned number of patients changed from 300 to 340.
- 03 Feb 2026 New trial record